CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Current assets:
Cash and cash equivalents	$ 65,477	$ 70,052
Short-term investments	278,187	402,301
Contracts receivable	6,921	1,242
Inventories	4,139	2,484
Other current assets	5,415	7,058
Total current assets	360,139	483,137
Property, plant and equipment, net	96,615	35,703
Licenses, net	9,036	12,288
Patents, net	16,259	15,821
Deposits and other assets	2,845	3,528
Total assets	484,894	550,477
Current liabilities:
Accounts payable	8,300	6,523
Accrued compensation	9,183	6,831
Accrued liabilities	18,655	12,389
Current portion of long-term obligations	3,390	5,645
Current portion of deferred contract revenue	36,584	74,502
Total current liabilities	76,112	105,890
Long-term deferred contract revenue	17,474	50,413
2 5/8 percent convertible subordinated notes	141,448	132,895
Long-term obligations, less current portion	4,125	5,720
Long-term financing liability for leased facility	69,877	10,147
Investment in Regulus Therapeutics Inc.	4,424	870
Total liabilities	313,460	305,935
Stockholders' equity:
Common stock, $0.001 par value; 200,000,000 shares authorized, 100,042,976 and 99,393,780 shares issued and outstanding at December 31, 2011 and 2010, respectively	100	99
Additional paid-in capital	1,013,592	1,000,181
Accumulated other comprehensive income (loss)	(770)	949
Accumulated deficit	(841,488)	(756,687)
Total stockholders' equity	171,434	244,542
Total liabilities and stockholders' equity	$ 484,894	$ 550,477